Aneeqa Zafar, Hanna Yakubi, Benjamin Moskoff, Kathryn Alvarez, Amber Tang, Joseph Tuscano, Aaron Rosenberg
{"title":"Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.","authors":"Aneeqa Zafar, Hanna Yakubi, Benjamin Moskoff, Kathryn Alvarez, Amber Tang, Joseph Tuscano, Aaron Rosenberg","doi":"10.1159/000550253","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS.</p><p><strong>Case presentation: </strong>We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up.</p><p><strong>Conclusion: </strong>These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"284-292"},"PeriodicalIF":0.7000,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956320/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000550253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS.
Case presentation: We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up.
Conclusion: These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
